Khanlou H, Tsiodras S, Eiger G, Abousy K, Goldberg S, Nakhjavan F, Yazdanfar S
Department of Pulmonary and Critical Care Medicine, Albert Einstein Medical Center, Philadelphia, PA 19141, USA.
Cathet Cardiovasc Diagn. 1998 Jul;44(3):313-6. doi: 10.1002/(sici)1097-0304(199807)44:3<313::aid-ccd14>3.0.co;2-l.
We describe two cases of diffuse alveolar hemorrhage and development of ARDS in patients who underwent percutaneous transluminal coronary angioplasty (PTCA) with stenting in whom Abciximab (ReoPro) was used in combination with other agents interfering with the hemostatic mechanism. The development of pulmonary infiltrates, associated with a fall in hemoglobin after the administration of Abciximab, should strongly suggest the possibility of diffuse alveolar hemorrhage. Physicians should be aware of the possible association between the use of Abciximab and the development of alveolar hemorrhage.
我们描述了两例接受经皮冠状动脉腔内血管成形术(PTCA)并置入支架且使用阿昔单抗(ReoPro)联合其他干扰止血机制药物的患者发生弥漫性肺泡出血和急性呼吸窘迫综合征(ARDS)的病例。在使用阿昔单抗后出现肺部浸润并伴有血红蛋白下降,这强烈提示弥漫性肺泡出血的可能性。医生应意识到使用阿昔单抗与肺泡出血发生之间可能存在的关联。